Earnings Feed
Start Free
|4Jul 23, 7:11 PM ET

LVP III Partners LP 4

4 · OncoMed Pharmaceuticals Inc · Filed Jul 23, 2013

Insider Transaction Report

Form 4
Period: 2013-07-23
OncoMed Pharmaceuticals IncOMED
LVP GP I, LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2013-07-23$17.00/sh+2,161$36,737→ 67,409 total(indirect: Directly owned by Associates)
  • Conversion

    Series B Preferred Stock

    2013-07-23−279,135→ 0 total(indirect: Directly owned by LVP II)
    → Common Stock (279,135 underlying)
  • Conversion

    Series B Preferred Stock

    2013-07-23−30,599→ 0 total(indirect: Directly owned by Associates)
    → Common Stock (30,599 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2013-07-23−17,324→ 0 total(indirect: Directly owned by Partners)
    → Common Stock (17,324 underlying)
  • Conversion

    Common Stock

    2013-07-23+100,000→ 100,000 total(indirect: Directly owned by LVP I)
  • Conversion

    Common Stock

    2013-07-23+74,142→ 239,618 total(indirect: Directly owned by LVP I)
  • Conversion

    Common Stock

    2013-07-23+426,315→ 426,315 total(indirect: Directly owned by LVP II)
  • Purchase

    Common Stock

    2013-07-23$17.00/sh+33,834$575,178→ 1,055,363 total(indirect: Directly owned by LVP II)
  • Purchase

    Common Stock

    2013-07-23$17.00/sh+43,223$734,791→ 1,348,212 total(indirect: Directly owned by LVP III)
  • Conversion

    Series B Preferred Stock

    2013-07-23−611,995→ 0 total(indirect: Directly owned by LVP III)
    → Common Stock (611,995 underlying)
  • Conversion

    Series B Preferred Stock

    2013-07-23−15,299→ 0 total(indirect: Directly owned by Partners)
    → Common Stock (15,299 underlying)
  • Conversion

    Common Stock

    2013-07-23+65,476→ 165,476 total(indirect: Directly owned by LVP I)
  • Conversion

    Common Stock

    2013-07-23+316,079→ 1,021,529 total(indirect: Directly owned by LVP II)
  • Conversion

    Common Stock

    2013-07-23+15,299→ 15,299 total(indirect: Directly owned by Partners)
  • Purchase

    Common Stock

    2013-07-23$17.00/sh+1,080$18,360→ 33,703 total(indirect: Directly owned by Partners)
  • Conversion

    Series A Preferred Stock

    2013-07-23−100,000→ 0 total(indirect: Directly owned by LVP I)
    → Common Stock (100,000 underlying)
  • Conversion

    Series B Preferred Stock

    2013-07-23−65,476→ 0 total(indirect: Directly owned by LVP I)
    → Common Stock (65,476 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2013-07-23−316,079→ 0 total(indirect: Directly owned by LVP II)
    → Common Stock (316,079 underlying)
  • Conversion

    Common Stock

    2013-07-23+692,994→ 1,304,989 total(indirect: Directly owned by LVP III)
  • Conversion

    Common Stock

    2013-07-23+30,599→ 30,599 total(indirect: Directly owned by Associates)
  • Conversion

    Common Stock

    2013-07-23+279,135→ 705,450 total(indirect: Directly owned by LVP II)
  • Conversion

    Common Stock

    2013-07-23+611,995→ 611,995 total(indirect: Directly owned by LVP III)
  • Conversion

    Common Stock

    2013-07-23+34,649→ 65,248 total(indirect: Directly owned by Associates)
  • Conversion

    Common Stock

    2013-07-23+17,324→ 32,623 total(indirect: Directly owned by Partners)
  • Conversion

    Series A Preferred Stock

    2013-07-23−426,315→ 0 total(indirect: Directly owned by LVP II)
    → Common Stock (426,315 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2013-07-23−74,142→ 0 total(indirect: Directly owned by LVP I)
    → Common Stock (74,142 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2013-07-23−692,994→ 0 total(indirect: Directly owned by LVP III)
    → Common Stock (692,994 underlying)
  • Purchase

    Common Stock

    2013-07-23$17.00/sh+7,937$134,929→ 247,555 total(indirect: Directly owned by LVP I)
  • Conversion

    Series B-1 Preferred Stock

    2013-07-23−34,649→ 0 total(indirect: Directly owned by Associates)
    → Common Stock (34,649 underlying)
Holdings

  • Common Stock

    (indirect: Directly owned by LVPMC)
    43,859
Footnotes (5)
  • [F1]Each share of Series A, Series B and Series B-1 Preferred Stock automatically converted on a one-to-one basis into Common Stock immediately prior to the consummation of the Issuer's initial public offering on July 23, 2013.
  • [F2]The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures I, L.P. ("LVP I"), LVP Life Science Ventures II, L.P. ("LVP II"), LVP Life Science Ventures III, L.P ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP I, LLC ("GP I") is the general partner of LVP I, LVP GP II, LLC ("GP II") is the general partner of LVP II and LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. (Continued on Footnote 3)
  • [F3]GP I, GP II and GP III may be deemed to have sole voting power and dispositive power over the shares held by LVP I, LVP II, LVP III, Associates and Partners. Each of GP I, GP II, GP III and Patrick Latterell, the managing member of each of GP I, GP II and GP III and the manager of LVPMC may be deemed to share voting and dispositive power over the reported securities and disclaim beneficial ownership of the reported securities held by LVPMC, LVP I, LVP II, LVP III, Associates and Partners except to the extent of any pecuniary interest therein. James W. Woody, M.D., Ph.D., as a member of each of GP I, GP II and GP III, may be deemed to share voting and dispositive power over the reported securities held by LVP I, LVP II, LVP III, Associates and Partners, and disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
  • [F4]The securities are immediately convertible.
  • [F5]The expiration date is not relevant to the conversion of these securities.

Documents

1 file
  • 4
    rrd386050.xmlPrimary